Peptide education
Methylene Blue
Methylthioninium chloride · ProvayBlue
Methylene blue is a synthetic dye that became a drug: a redox-active thiazine compound, sold as the prescription injection PROVAYBLUE, used to treat acquired methemoglobinemia, a blood disorder in which hemoglobin cannot carry oxygen properly. It is not a peptide and not a supplement, though it circulates in peptide and nootropic circles because the same electron-shuttling chemistry that fixes methemoglobin also works inside mitochondria. That chemistry is real. The leap from a monitored IV drug to daily oral drops for focus and longevity has no outcome trial behind it, and the drug's interaction risks make casual use a different category of gamble.
Methylene blue is a real prescription drug with exactly one labeled use: IV treatment of acquired methemoglobinemia. The nootropic reputation is mechanism talk, and the boxed warning for serotonin syndrome is the part of the label the wellness posts leave out.
Overview
Quick answer
The word "methylene blue" can refer to very different things: an FDA-labeled injectable drug, pharmacy or clinic material, laboratory dye, aquarium or industrial products, gray-market bottles, and online nootropic drops. The official PROVAYBLUE label is the reference point here; cognition, mitochondrial, anti-aging, and redox claims belong to the wellness and nootropic conversation, not to the approved-drug label.
What is it?
Methylene blue is methylthioninium chloride, a thiazine dye with oxidation-reduction activity. As the drug PROVAYBLUE, it is an IV treatment for acquired methemoglobinemia, where it helps convert abnormal methemoglobin back to working hemoglobin.
Why does it show up with peptides?
Audience overlap. The same people shopping for mitochondrial peptides get sold methylene blue as mitochondrial support, because it can shuttle electrons in the respiratory chain. It is a drug and a dye, not a peptide, and it has real pharmacology behind that fact.
What do people talk about it for?
Focus, memory, mood, energy, anti-aging, and stacks with NAD+ or MOTS-c. None of that appears in the drug label, and no controlled human outcome trial supports it.
What about nootropic claims?
The mechanism is plausible enough to explain the interest: electron shuttling past complex I-III bottlenecks, plus MAO-A inhibition. Plausible mechanism plus a drug label for a blood disorder is not evidence that low-dose drops sharpen your mind.
What route and amount patterns are in the drug label?
The label pattern is 1 mg/kg IV over 5 to 30 minutes, with a possible second 1 mg/kg dose an hour later, from a 5 mg/mL single-dose vial. It explicitly says not to inject subcutaneously. Community oral routines of about 4 to 15 mg a day are a different, unlabeled exposure.
What is the bottom line?
Treat it like the drug it is. It carries a boxed warning for serotonin syndrome with serotonergic drugs and opioids, a hard contraindication in G6PD deficiency, and an overdose section. None of that makes it into the blue-drop marketing.
Reported practice
Commonly reported protocol
Community low-dose cognitive protocols. Community-reported patterns, not verified by controlled human trials and not a use recommendation. Full use-pattern detail
Evidence
Evidence snapshot
The official PROVAYBLUE label identifies pediatric and adult acquired methemoglobinemia as the medical indication.
The label gives an intravenous regimen and states that subcutaneous administration is not a labeled route.
The redox mechanism explains why methylene blue shows up in mitochondrial and nootropic conversations, but those benefits sit outside the PROVAYBLUE label.
The boxed warning highlights serious or fatal serotonin syndrome risk when methylene blue is combined with serotonergic drugs and opioids.
PROVAYBLUE is a sterile, labeled, single-dose injectable product. Online drops, laboratory dyes, aquarium products, and gray-market bottles are different product situations.
Claims
Common claims vs evidence
| Claim | Human evidence | Mechanistic evidence | Anecdotal evidence | Verdict |
|---|---|---|---|---|
| Methylene blue treats acquired methemoglobinemia. | Supported for the labeled product. The label identifies PROVAYBLUE for pediatric and adult acquired methemoglobinemia and describes adult and pediatric clinical evidence tied to methemoglobin reduction. | The label describes methylene blue as promoting redox conversion of methemoglobin back toward hemoglobin through leucomethylene blue. | Online summaries sometimes shorten this into "methylene blue improves oxygen," which can blur a specific emergency-style drug indication with broad wellness language. | Accurate only when stated as the labeled acquired-methemoglobinemia use for PROVAYBLUE or another appropriate medical methylene blue product. |
| Methylene blue is a nootropic. | The PROVAYBLUE label is not a cognitive-benefit source. It does not study memory enhancement, focus, mood, or productivity outcomes. | Redox pharmacology makes the brain and mitochondrial conversation understandable, but the label mechanism is about methemoglobin reduction, not cognitive enhancement. | Nootropic and longevity discussion often treats low-dose oral methylene blue as a focus or energy tool, especially when paired with mitochondrial language. | Discussable as a market claim, but not as a PROVAYBLUE-label benefit. |
| Methylene blue supports mitochondria and redox balance. | The labeled human use depends on redox chemistry in methemoglobinemia. That is not the same as outcome evidence for energy, endurance, cognition, or aging claims in wellness use. | Methylene blue can participate in oxidation-reduction chemistry. The label specifically describes conversion to leucomethylene blue and reduction of ferric iron in methemoglobin. | Peptide-adjacent discussions often place it near NAD+, glutathione, SS-31, MOTS-c, and other mitochondrial products. Those comparisons can explain search interest without turning those discussions into a protocol. | The redox mechanism is real; broad mitochondrial wellness claims remain outside the PROVAYBLUE label. |
| All methylene-blue products are interchangeable. | The label supports only the specific prescription injectable product format and its medical use. Other liquids, powders, dyes, bottles, or marketplace products still need their own identity, impurity, route, and safety evidence. | Product form changes exposure, impurities, sterility, route risk, concentration, excipients, storage, and contamination concerns. | Online methylene blue conversations often collapse all blue liquids into one name, then discuss drops, oral use, or stacks beside injectable drug facts. | Product identity and route are the risk. A prescription IV solution, a lab dye, an aquarium product, and an oral-drop bottle can share a color while carrying very different impurity, concentration, and exposure problems. |
| The main safety issue is just blue urine or staining. | Blue discoloration is real, but the label also includes a boxed warning for serotonin syndrome, contraindications, hemolytic anemia risk, monitoring interference, pregnancy and lactation concerns, renal and hepatic impairment issues, and overdose toxicity. | A redox-active dye can affect hemoglobin chemistry and also interfere with monitoring and lab interpretation. | Wellness discussions often make the compound sound simple because the visible color effect is easy to notice. | The interaction and monitoring issues matter more than the color novelty. |
Bottom line
Main takeaway
Methylene blue is a prescription drug for a blood disorder, not a vitamin. The wellness version borrows the drug's credibility and skips its warnings.
Two facts anchor any decision: the only labeled use is IV methemoglobinemia treatment, and the serotonin-syndrome interaction risk applies to anyone on serotonergic medication regardless of dose or route.
The PROVAYBLUE label is the entire solid ground here: indication, dosing, interactions, monitoring interference, half-life. Everything nootropic or mitochondrial beyond that is mechanism and marketing.
Identity
What it is
Methylene blue is methylthioninium chloride, a water-soluble thiazine dye that has been in medicine for over a century. Its current FDA-labeled form is PROVAYBLUE, a sterile 5 mg/mL IV injection for acquired methemoglobinemia.
Its redox chemistry is why it straddles two worlds. In the blood it converts to leucomethylene blue and reduces methemoglobin back toward hemoglobin. In mitochondria it can shuttle electrons around respiratory-chain bottlenecks, and it inhibits MAO-A: enough real pharmacology to fuel a nootropic reputation, and enough to cause real harm.
The name covers wildly different products: a prescription injection, compounded material, oral drops, laboratory dye, aquarium treatments. They share a color and a molecule name. They do not share purity, concentration, or safety.
How people talk about it online
Nootropic forums discuss methylene blue as a daily low-dose tool, typically 4 to 15 mg orally, with pharmaceutical-grade sourcing treated as the key safety step. The enthusiasm is real, and so is the absence of controlled outcome data behind it.
The discussions consistently underweight the interaction problem. Methylene blue inhibits MAO-A, and combining it with SSRIs, SNRIs, other serotonergic drugs, opioids, or dextromethorphan can trigger serotonin syndrome, which is why the prescription label leads with a boxed warning.
Product confusion is the other recurring hazard: lab dye, aquarium product, and gray-market liquid get discussed as if they were the prescription drug. Contamination and concentration problems in that market are not hypothetical.
Use context
Routes, doses, and cycle patterns
The label gives an IV methemoglobinemia regimen. Oral drops, subcutaneous use, nootropic stacks, and wellness cycles are separate product and route claims that need their own evidence.
Human studies and product labels
PROVAYBLUE labeled regimen
- Purpose
- Treatment of acquired methemoglobinemia
- Context
- DailyMed prescription drug label
- Route
- Intravenous infusion
- Amount
- 1 mg/kg
- Frequency
- Label-described initial dose with a possible repeat dose in defined treatment circumstances
- Duration
- Infused over 5 to 30 minutes; maximum recommended number of doses is two
This is the clearest drug-label amount and timing pattern. It is a medical treatment regimen, not a wellness protocol.
Moderate or severe renal impairment label pattern
- Purpose
- Acquired methemoglobinemia with reduced renal function
- Context
- DailyMed prescription drug label
- Route
- Intravenous infusion
- Amount
- Single 1 mg/kg dose
- Frequency
- Single dose; if symptoms persist after one hour, alternative interventions are considered
- Duration
- Infused over 5 to 30 minutes
The label reports increased methylene blue exposure in renal impairment, which is why this dosing language differs from the general repeat-dose pathway.
Product form and preparation details
- Purpose
- Prescription injectable product identity
- Context
- DailyMed prescription drug label
- Route
- Intravenous use only; not subcutaneous
- Amount
- 5 mg/mL, supplied as 10 mg/2 mL or 50 mg/10 mL single-dose containers
- Frequency
- Single-dose vial or ampule; discard unused portion
- Duration
- Diluted solution is used immediately after preparation when dilution is used
The label describes a sterile dark-blue solution, not a general methylene-blue product category. It also notes dilution with 5% dextrose when dilution is used and warns against sodium chloride dilution.
Real-world discussion
Community low-dose cognitive protocols
- Purpose
- Cognition and mitochondrial discussion
- Context
- Biohacking forums and vendors
- Route
- Oral solutions or capsules
- Amount
- Community protocols usually describe low daily amounts around 4 to 15 mg total, far below the labeled 1 mg per kg IV dose, with pharmaceutical-grade (USP) sourcing treated as essential in community guidance.
- Frequency
- Once daily in most descriptions
- Duration
- Ongoing or cycled in community logs
Methylene blue is a dye and drug, not a peptide. The serious interaction risk with serotonergic drugs (serotonin syndrome) and the G6PD-deficiency contraindication are the dominant safety facts, and aquarium or industrial-grade product is a real contamination story. Reported as context, not a recommendation.
What varies
- Route: the label is intravenous only and specifically excludes subcutaneous administration.
- Product form: PROVAYBLUE is a 5 mg/mL sterile single-dose injection, not a general blue-liquid category.
- Amount: the prescription-drug amount is weight-based at 1 mg/kg.
- Repeat dosing: the label allows one repeat dose after one hour in the general pathway, with a maximum recommended number of two doses.
- Renal function: methylene blue exposure rises in renal impairment, and the label changes the repeat-dose approach for moderate or severe renal impairment.
- Drug interactions: serotonergic drugs, opioids, and dextromethorphan are central safety concerns.
- Monitoring: pulse oximetry, BIS monitoring, and some urine tests can be affected by methylene blue.
Human data
Human evidence
The human evidence on this page is the PROVAYBLUE label: clinical support for treating acquired methemoglobinemia, plus an unusually instructive safety section. That section documents serotonin-syndrome risk with serotonergic drugs and opioids, hemolysis risk in G6PD deficiency, interference with pulse oximetry and anesthesia monitoring, and overdose toxicity. What the label does not contain is any study of cognition, energy, mood, or aging. For the uses that made methylene blue famous online, there is no comparable human outcome evidence at all.
Evidence maturity
Methylene blue is a real prescription drug for one indication; the nootropic and mitochondrial claims behind its wellness fame have no comparable human outcome evidence.
A thiazine dye whose oxidation-reduction chemistry converts methemoglobin back toward hemoglobin.
PROVAYBLUE is the FDA-labeled intravenous product for acquired methemoglobinemia, supported by label-described clinical evidence.
Electron-shuttling in the mitochondrial transport chain and MAO-A inhibition explain the cognition and mitochondrial attention, but mechanism is not outcome evidence.
No controlled human outcome trials support cognition, energy, or anti-aging use, while the boxed warning on serotonin syndrome documents the concrete risk.
| Study / evidence area | Population | Design | Product context | Main outcome | Limitations | Weight |
|---|---|---|---|---|---|---|
| PROVAYBLUE acquired-methemoglobinemia label | Pediatric and adult patients with acquired methemoglobinemia | Prescription drug label summarizing adult clinical studies and pediatric case-series support | FDA-labeled intravenous PROVAYBLUE injection | The label supports treatment of acquired methemoglobinemia and describes methemoglobin reduction after intravenous dosing in adult studies. | This evidence is tied to an IV drug used for methemoglobinemia. It leaves open whether oral drops, gray-market liquids, laboratory products, aquarium products, cognitive use, mitochondrial wellness, or anti-aging claims have the right exposure, impurities, monitoring, or outcome support. | Strong for labeled identity and medical use; weak for wellness claims |
| PROVAYBLUE safety and interaction labeling | People receiving methylene blue class products in medical settings | Prescription drug label warnings, precautions, pharmacology, and interaction information | FDA-labeled intravenous PROVAYBLUE injection | The label highlights serotonin syndrome risk with serotonergic drugs and opioids, G6PD contraindication, hemolytic anemia, hypersensitivity, monitoring interference, renal and hepatic impairment issues, pregnancy and lactation cautions, and overdose toxicity. | Safety labeling for a medical product does not make nonmedical products safer. It shows why casual wellness use can miss important drug-risk questions. | Strong for warnings and product-specific risk |
Cautions
Safety and unknowns
- The boxed warning is the headline safety issue: serious or fatal serotonin syndrome can occur when methylene blue is used with serotonergic drugs or opioids. The label names SSRIs, SNRIs, MAOIs, opioids, and dextromethorphan as part of this risk discussion.
- PROVAYBLUE is contraindicated in people with severe hypersensitivity to methylene blue or another thiazine dye and in people with G6PD deficiency because of hemolytic anemia risk.
- Hemolysis and anemia can occur, and anemia may be delayed. The label also notes lack of effectiveness or rebound in some methemoglobinemia causes, including aryl amines and sulfa drugs such as dapsone.
- Methylene blue can interfere with pulse oximeter readings, BIS anesthesia monitoring, and urine tests that rely on blue indicators.
- Confusion, dizziness, and visual disturbances are label-listed concerns after treatment. The label also mentions phototoxicity and blue discoloration of skin and body fluids.
- Pregnancy, lactation, renal impairment, and hepatic impairment all change the risk discussion. The label says breastfeeding should be discontinued during and for up to 8 days after treatment.
- The overdose section is a reminder that more is not benign: hypotension, wheezing, reduced oxygenation, neurologic symptoms, hemolysis, and death are described at higher methylene blue class exposures.
Product quality
A vial label is only a starting point
PROVAYBLUE is a sterile prescription injectable product with a stated concentration, container format, storage language, dilution instructions, and single-dose handling. Those details do not automatically apply to drops, dyes, lab materials, aquarium products, or gray-market bottles.
A methylene-blue product comparison starts with the exact product, route, concentration, excipients, sterility, storage, lot traceability, and intended use.
The wellness market often treats molecule identity as if it were enough. For methylene blue, product identity and drug-interaction risk are part of the core issue.
Exact product identity
PROVAYBLUE injection, oral drops, laboratory dye, and aquarium products are different product situations even when the molecule name overlaps.
Route and sterility
The label is intravenous-only medical use. A non-drug product has to prove injectable sterility and route suitability on its own.
Concentration
The labeled drug is 5 mg/mL. Other products may use different or unclear concentrations.
Interactions
Serotonergic drugs, opioids, dextromethorphan, renal function, hepatic function, and G6PD status can matter more than the wellness claim being discussed.
Storage and light protection
The labeled product has room-temperature storage, no refrigeration or freezing, and original-package light-protection instructions.
Mechanism
How it is proposed to work
Methylene blue can move electrons in redox reactions. In its approved medical use, it helps convert methemoglobin back toward normal hemoglobin chemistry, which is why it is used for acquired methemoglobinemia.
The label describes methylene blue as a water-soluble thiazine dye that promotes non-enzymatic redox conversion of methemoglobin to hemoglobin.
In the body, methylene blue is first converted to leucomethylene blue by NADPH reductase. Leucomethylene blue then reduces ferric iron in methemoglobin to the ferrous state of normal hemoglobin.
That redox chemistry is why methylene blue shows up in mitochondrial and nootropic marketing, but the prescription-drug mechanism is still the hemoglobin chemistry described in the drug label.
Pharmacokinetic details in the label also show why casual use is easy to misread: methylene blue has about a 24-hour half-life in humans, is extensively metabolized, and has renal-impairment exposure changes.
Methylene blue is a thiazine dye that shuttles electrons in the mitochondrial transport chain, bypassing complex I-III bottlenecks via cytochrome c: the basis of its mitochondrial-optimization reputation. It is also a potent MAO-A inhibitor, which is the source of the serotonin-syndrome interaction risk with serotonergic drugs.
FAQ
Common questions
Is there support for methylene blue as a nootropic or longevity protocol?
People do discuss methylene blue that way, usually around redox and mitochondrial language. The PROVAYBLUE label answers a different question: acquired-methemoglobinemia treatment with IV-only medical context and important interaction warnings. It does not answer personal use, dose planning, or stacking.
Details
Technical details
Sources
References
- 1.
DailyMed. PROVAYBLUE (methylene blue) injection label 2026.
Accessed 2026-06-09.
Official PROVAYBLUE label source for acquired methemoglobinemia indication, single-dose injectable product framing, contraindications, and serotonergic-syndrome risk context.